Skip to content

Xencor XNCR Royalties — Expected royalty interest payments

Similar metrics at other companies

Syndax Pharmaceuticals logo
SNDXRoyalty Interest Financing Less Current Portion
$343.91M+3.7%
BioCryst Pharmaceuticals logo
BCRXRoyalty financing obligations
$40.32M+17.5%
BioCryst Pharmaceuticals logo
BCRXInterest paid, royalty financing obligations
$8.47M-41.8%
BioCryst Pharmaceuticals logo
BCRXRoyalty financing obligations
$407.18M-12.7%
BioCryst Pharmaceuticals logo
BCRXNon-cash interest expense on royalty financing obligations
$13.29M-1.6%
BioCryst Pharmaceuticals logo
BCRXRepayment Of Royalty Financing Liabilities, Principal
$476K

Other financials

Income statement

See full
Revenue$4.5M-86.2%
Operating income-$77.9M-80.3%
Net income-$128.9M-166%
EPS (diluted)-$1.71-159%

Balance sheet

See full
Cash & equivalents$14.2M-64.3%
Total debt$175.2M-21.2%
Total equity$515.6M-19.4%
Total assets$736.8M-18.6%

Cash flow

See full
Operating cash flow-$67.6M-317%
CapEx$610.0K-57.8%
Free cash flow-$68.2M-286%

Valuation

See full
Market cap$1.07B+79.8%
Enterprise value$1.23B+58.6%
P/S11×+6.3×

Profitability

See full
Operating margin-217.9%+425pp
Net margin-177.1%+16.5pp
FCF margin-194%+166pp

Returns & leverage

See full
Return on equity-29.8%-2.7pp
Debt / equity0.3×0.0×
Current ratio6.6×+0.7×

Where this comes from

Reported directly by Xencor in its filing.

Tagged under the XBRL concept xncr:ExpectedRoyaltyInterestPayments.

The official record: Xencor’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Xencor's royalties — expected royalty interest payments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Xencor's royalties — expected royalty interest payments?
Xencor (XNCR) reported royalties — expected royalty interest payments of $12M in Q4 2028.
What does royalties — expected royalty interest payments mean?
This metric estimates the future cash outflows or obligations related to interest payments on royalty-backed financing or debt instruments. It is used to assess the cost of capital associated with monetizing future royalty streams.